I was hoping cash burn might decrease in this current quarter, since the March quarter had included a sizeable $5m milestone payment on the onset of patient dosing. Interesting that Coppo sees it increasing.
My cursory analysis had led me to thinking a deal with up-front cash for working capital could come before a CR is needed. Coppo is now leaning to a CR.
I’d go with Coppo here, team. I would assume they have crunched more numbers than me.
research reports and media, page-2751
-
- There are more pages in this discussion • 1,654 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.3¢ |
Change
0.013(5.68%) |
Mkt cap ! $78.70M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $18.36K | 79.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5397 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 149266 | 10 |
View Market Depth
| Last trade - 12.36pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |